Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Persson

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Cancers|October 13, 2021
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World EfficacyMette T Mouritzen, Andreas Carus, Morten Ladekarl, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 22, 2018
Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetesN Tofte, M Lindhardt, K Adamova, et al.
Acta Oncologica (Stockholm, Sweden)|January 11, 2022
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world studyMette T Mouritzen, Karen F Junker, Andreas Carus, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Cancers|October 13, 2021
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World EfficacyMette T Mouritzen, Andreas Carus, Morten Ladekarl, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 22, 2018
Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetesN Tofte, M Lindhardt, K Adamova, et al.
Acta Oncologica (Stockholm, Sweden)|January 11, 2022
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world studyMette T Mouritzen, Karen F Junker, Andreas Carus, et al.
Pageof 7